MedTrace Logo

Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma

NCT02060890 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-12-12

Study results available
· View outcomes & findings →

Summary

This current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole genome sequencing, exome analysis, and RNA sequencing as well as predictive modeling. This new treatment strategy has shown promising results in adult patients with other solid tumors.

Conditions

  • Adult Glioblastoma

Interventions

OTHER

specialized tumor board recommendation

feasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.

Sponsors & Collaborators

Principal Investigators

  • Michael Prados, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-09-03
Completion
2017-05-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02060890 on ClinicalTrials.gov